Literature DB >> 20583978

Modulation of the Rho/ROCK pathway in heart and lung after thorax irradiation reveals targets to improve normal tissue toxicity.

Virginie Monceau1, Nadia Pasinetti, Charlotte Schupp, Fred Pouzoulet, Paule Opolon, Marie-Catherine Vozenin.   

Abstract

The medical options available to prevent or treat radiation-induced injury are scarce and developing effective countermeasures is still an open research field. In addition, more than half of cancer patients are treated with radiation therapy, which displays a high antitumor efficacy but can cause, albeit rarely, disabling long-term toxicities including radiation fibrosis. Progress has been made in the definition of molecular pathways associated with normal tissue toxicity that suggest potentially effective therapeutic targets. Targeting the Rho/ROCK pathway seems a promising anti-fibrotic approach, at least in the gut; the current study was performed to assess whether this target was relevant to the prevention and/or treatment of injury to the main thoracic organs, namely heart and lungs. First, we showed activation of two important fibrogenic pathways (Smad and Rho/ROCK) in response to radiation-exposure to adult cardiomyocytes; we extended these observations in vivo to the heart and lungs of mice, 15 and 30 weeks post-irradiation. We correlated this fibrogenic molecular imprint with alteration of heart physiology and long-term remodelling of pulmonary and cardiac histological structures. Lastly, cardiac and pulmonary radiation injury and bleomycin-induced pulmonary fibrosis were successfully modulated using Rho/ROCK inhibitors (statins and Y-27632) and this was associated with a normalization of fibrogenic markers. In conclusion, the present paper shows for the first time, activation of Rho/ROCK and Smad pathways in pulmonary and cardiac radiation-induced delayed injury. Our findings thereby reveal a safe and efficient therapeutic opportunity for the abrogation of late thoracic radiation injury, potentially usable either before or after radiation exposure; this approach is especially attractive in (1) the radiation oncology setting, as it does not interfere with prior anti-cancer treatment and in (2) radioprotection, as applicable to the treatment of established radiation injury, for example in the case of radiation accidents or acts of terrorism.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20583978     DOI: 10.2174/1389450111009011395

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  22 in total

1.  Relaxin regulates myofibroblast contractility and protects against lung fibrosis.

Authors:  Xiangwei Huang; Ying Gai; Naiheng Yang; Baogen Lu; Chrishan S Samuel; Victor J Thannickal; Yong Zhou
Journal:  Am J Pathol       Date:  2011-10-06       Impact factor: 4.307

2.  Role of Interleukin-1 in Radiation-Induced Cardiomyopathy.

Authors:  Eleonora Mezzaroma; Ross B Mikkelsen; Stefano Toldo; Adolfo G Mauro; Khushboo Sharma; Carlo Marchetti; Asim Alam; Benjamin W Van Tassell; David A Gewirtz; Antonio Abbate
Journal:  Mol Med       Date:  2015-03-26       Impact factor: 6.354

3.  Protection from Radiation-Induced Pulmonary Fibrosis by Peripheral Targeting of Cannabinoid Receptor-1.

Authors:  Irina Bronova; Brett Smith; Bulent Aydogan; Ralph R Weichselbaum; Kiran Vemuri; Katalin Erdelyi; Alex Makriyannis; Pal Pacher; Evgeny V Berdyshev
Journal:  Am J Respir Cell Mol Biol       Date:  2015-10       Impact factor: 6.914

Review 4.  Molecular mechanisms and treatment of radiation-induced lung fibrosis.

Authors:  Nian-Hua Ding; Jian Jian Li; Lun-Quan Sun
Journal:  Curr Drug Targets       Date:  2013-10       Impact factor: 3.465

Review 5.  Effects of ionizing radiation on the heart.

Authors:  Marjan Boerma; Vijayalakshmi Sridharan; Xiao-Wen Mao; Gregory A Nelson; Amrita K Cheema; Igor Koturbash; Sharda P Singh; Alan J Tackett; Martin Hauer-Jensen
Journal:  Mutat Res Rev Mutat Res       Date:  2016-07-10       Impact factor: 5.657

6.  Syndecan-2 Attenuates Radiation-induced Pulmonary Fibrosis and Inhibits Fibroblast Activation by Regulating PI3K/Akt/ROCK Pathway via CD148.

Authors:  Konstantin Tsoyi; Sarah G Chu; Nasly G Patino-Jaramillo; Julie Wilder; Julian Villalba; Melanie Doyle-Eisele; Jacob McDonald; Xiaoli Liu; Souheil El-Chemaly; Mark A Perrella; Ivan O Rosas
Journal:  Am J Respir Cell Mol Biol       Date:  2018-02       Impact factor: 6.914

Review 7.  Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease.

Authors:  John D Groarke; Paul L Nguyen; Anju Nohria; Roberto Ferrari; Susan Cheng; Javid Moslehi
Journal:  Eur Heart J       Date:  2013-05-10       Impact factor: 29.983

8.  Screening for YAP Inhibitors Identifies Statins as Modulators of Fibrosis.

Authors:  Daniela M Santos; Lorena Pantano; Gina Pronzati; Paula Grasberger; Clemens K Probst; Katharine E Black; Jillian J Spinney; Lida P Hariri; Royale Nichols; Yufei Lin; Michael Bieler; Peter Seither; Paul Nicklin; David Wyatt; Andrew M Tager; Benjamin D Medoff
Journal:  Am J Respir Cell Mol Biol       Date:  2020-04       Impact factor: 6.914

9.  Inhibition of Rac1 signaling by lovastatin protects against anthracycline-induced cardiac toxicity.

Authors:  J Huelsenbeck; C Henninger; A Schad; K J Lackner; B Kaina; G Fritz
Journal:  Cell Death Dis       Date:  2011-08-11       Impact factor: 8.469

10.  Enhanced sensitivity to low dose irradiation of ApoE-/- mice mediated by early pro-inflammatory profile and delayed activation of the TGFβ1 cascade involved in fibrogenesis.

Authors:  Virginie Monceau; Lydia Meziani; Carine Strup-Perrot; Eric Morel; Magret Schmidt; Julia Haagen; Brigitte Escoubet; Wolfgang Dörr; Marie-Catherine Vozenin
Journal:  PLoS One       Date:  2013-02-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.